NCT03298087View on ClinicalTrials.gov

Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 1, 2018

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Newly Diagnosed Oligometastatic Prostate Cancer
Interventions
PROCEDURE

radical prostatectomy

surgical removal of the prostate

RADIATION

stereotactic body radiotherapy

Highly targeted radiation

DRUG

Leuprolide

Lowers serum testosterone

DRUG

apalutamide

antiandrogen

DRUG

abiraterone

Inhibits androgen synthesis

Trial Locations (3)

23249

Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond

90822

VA Long Beach Healthcare System, Long Beach, CA, Long Beach

90073-1003

VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT03298087 - Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer | Biotech Hunter | Biotech Hunter